Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05512754 · ClinicalTrials.gov registry record · Phase 4
Impact of Anti-inflammatory Medications in Patients With Elevated Serum Prostate-specific Antigen
A Phase 4 study of Elevated Serum PSA, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 3
- Study locations
NCT05512754 is a Phase 4 study of Elevated Serum PSA that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 200 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT05512754, a Phase 4 study of Elevated Serum PSA, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to assess the impact of ibuprofen in men with elevated serum PSA.
Conditions Studied
Interventions
- DRUG Ibuprofen 400 mg
Study Locations (3)
Illinois
- University of Chicago - Chicago
New York
- Albany Medical College - Albany
Pennsylvania
- The Pennsylvania State University at The Milton S. Hershey Medical Center - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-08-01 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05512754
The ClinicalTrials.gov registry entry for NCT05512754 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Elevated Serum PSA appearing as the primary indexed condition, and to 1 intervention - of which Ibuprofen 400 mg is the first listed.
NCT05512754 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Illinois, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05512754 about?
NCT05512754 is a clinical study titled "Impact of Anti-inflammatory Medications in Patients With Elevated Serum Prostate-specific Antigen". The purpose of this study is to assess the impact of ibuprofen in men with elevated serum PSA.
What is the current status of trial NCT05512754?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2022-08-01. Estimated completion is 2027-12-31.
What conditions does trial NCT05512754 study?
This clinical trial studies the following conditions: Elevated Serum PSA.
What interventions are being tested in trial NCT05512754?
The interventions under investigation include: Ibuprofen 400 mg (DRUG).
Who is sponsoring clinical trial NCT05512754?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05512754 being conducted?
This trial has 3 study locations across Illinois, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.